Photo: Navy Medicine / Unsplash
The deal brings a newly approved transcarotid stenting system with a built-in filter, plus peripheral clot-removal devices, under Medtronic's roof.
The Deal
Medtronic said on November 16 that it plans to acquire Contego Medical, a privately held company focused on carotid artery disease and peripheral thrombectomy, for $380 million plus potential payments after the deal closes [1]. Neither Medtronic's announcement nor Endovascular Today's report breaks down the size or triggers of those contingent payments [1,2].
The acquisition is expected to close in Medtronic's third fiscal quarter, subject to customary closing conditions [1]. Medtronic told investors the deal should be minimally dilutive to adjusted earnings per share in fiscal years 2027 and 2028 and neutral to accretive after that [1].
The two companies are not strangers. The purchase builds on an exclusive U.S. distribution agreement first announced in January 2025 [1,2], so in a sense Medtronic is buying the shop it was already stocking. Contego was founded by Ravish Sachar, MD, its chief executive, and Jay Yadav, MD, and is backed by venture investors including Hatteras Venture Partners, U.S. Venture Partners, Lightstone Ventures and Amzak Health [1].
David Moeller, who leads the company's peripheral vascular health business, said Medtronic intends "to become an undisputed leader in carotid revascularization" [1].
What Medtronic Is Getting
The centerpiece is the Neuroguard IEP Direct System. Contego announced on November 11 that the FDA had granted premarket approval (PMA) to that system and 510(k) clearance to the companion Neuroguard IEP Embolic Protection System [3]. Neither the company release nor Endovascular Today's coverage states the date FDA signed off, only the date of the announcement [3,4].
The system is used for transcarotid artery revascularization (TCAR), in which a stent is placed through a small incision at the neck rather than through a catheter threaded up from the groin or wrist. Contego's version combines two forms of protection against debris reaching the brain: reversal of blood flow in the carotid artery and a 40-micron filter built into the stent delivery device, which also carries the stent and a balloon [3]. Contego calls the approach "TCAR-IEP," for integrated embolic protection, and presents it as a new category of carotid revascularization [3]; Medtronic describes it as the first and only system of its kind [1]. Those are company characterizations.
The co-principal investigator of the pivotal study, Sean Lyden, MD, of Cleveland Clinic, said the filter was added "given the uncertainty in complete flow reversal" [3,4].
An earlier version, the Neuroguard IEP 3-in-1 system for stenting via the groin or wrist, received FDA approval in October 2024 and is already distributed by Medtronic [3,4]. The deal also includes Contego's Excipio thrombectomy devices, which Medtronic says complement its own Liberant thrombectomy system for peripheral vascular disease [1,2].
The Evidence and Its Limits
Approval rested on PERFORMANCE III, a prospective, multicenter investigational device exemption study. When results were first presented at the VIVA25 meeting in November 2025, Contego reported 146 patients treated at 26 sites [5]. The study recorded no strokes, myocardial infarctions, neurological deaths, cranial nerve injuries or stent thromboses at 30 days [3,5]. The primary endpoint, major adverse events through 30 days, occurred in 0.69% of the intention-to-treat population and 0% of the per-protocol cohort, which the company said was below the prespecified performance goal [3,5]. Medtronic's release cites a publication of the trial in the Journal of Vascular Surgery [1].
Those numbers are striking, but context matters. PERFORMANCE III was a single-arm study without a randomized comparison group, and the results reported here cover only 30 days. Zero events in about 150 patients is encouraging, yet a study of that size cannot rule out uncommon complications. Medtronic's own release cautions that outcomes from Contego's various studies should not be compared directly with one another [1], a caveat that applies at least as much to comparisons with other companies' trials.
What It Means for TCAR
TCAR as a procedure was pioneered by Silk Road Medical, which Boston Scientific acquired in a deal that closed in September 2024 at $27.50 per share, an enterprise value of about $1.18 billion [6]. With Contego, Medtronic gains its own TCAR system to compete in the same space, differentiated by the integrated filter.
Whether the added filter translates into better outcomes than flow reversal alone has not been tested head to head in the sources reviewed here. Medtronic notes that carotid artery disease accounts for about 20% of ischemic strokes [1], which helps explain why two of the largest device makers now want a seat at this table.
What Comes Next
The acquisition still has to close, and the contingent payments remain undisclosed. Clinicians will be watching for longer-term PERFORMANCE III follow-up, real-world registry data and pricing as Medtronic folds the system into its sales force.
This article is for informational purposes only and is not medical advice; readers with health questions should consult their clinician.
References
Medtronic. Medtronic to acquire Contego Medical, expanding access to next-generation carotid therapies. Medtronic News. November 16, 2026. https://news.medtronic.com/2026-11-16-Medtronic-to-acquire-Contego-Medical,-expanding-access-to-next-generation-carotid-therapies
Endovascular Today. Medtronic to acquire Contego Medical. Endovascular Today. November 16, 2026. https://evtoday.com/news/medtronic-to-acquire-contego-medical
Contego Medical. Contego Medical receives FDA approval for Neuroguard IEP Direct System (press release). Cath Lab Digest/HMP Global. November 11, 2026. https://www.hmpgloballearningnetwork.com/site/cathlab/press-release/contego-medical-receives-fda-approval-neuroguard-iep-direct-system
Endovascular Today. FDA approves Contego's Neuroguard IEP Direct system for TCAR-IEP. Endovascular Today. November 11, 2026. https://evtoday.com/news/fda-approves-contegos-neuroguard-iep-direct-system-for-tcar-iep
Endovascular Today. PERFORMANCE III 30-day outcomes reported for Contego Neuroguard TCAR-IEP system. Endovascular Today. November 3, 2025. https://evtoday.com/news/performance-iii-30-day-outcomes-reported-for-contego-neuroguard-tcar-iep-system
Boston Scientific. Boston Scientific closes acquisition of Silk Road Medical, Inc. Boston Scientific News. September 17, 2024. https://news.bostonscientific.com/2024-09-17-Boston-Scientific-Closes-Acquisition-of-Silk-Road-Medical,-Inc